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Background: We report results of the novel Washout Allometric Reference Method
(WARM) that uses estimates of cerebral blood flow and amyloid load from the same
[11C]Pittsburgh Compound B ([11C]PiB) retention maps in brain to distinguish between
patients with different forms dementia, including Alzheimer’s disease, and healthy
volunteers. The method introduces two approaches to the identification of brain
pathology related to amyloid accumulation, (1) a novel analysis of amyloid binding based
on the late washout of the tracer from brain tissue, and (2) the simultaneous estimation
of absolute cerebral blood flow indices (sCBF) from the early accumulation of the tracer
in brain tissue.
Objective: We tested the hypothesis that a change of cerebral blood flow is correlated
with the degree of tracer [11C]PiB retention, reflecting dendritic spine pathology and
consequent inhibition of brain energy metabolism and reduction of blood flow by
neurovascular coupling in neurodegenerative disorders, including Alzheimer’s disease.
Methods: Previously reported images of [11C]PiB retention in brain of 29 subjects with
cognitive impairment or dementia [16 Alzheimer’s Disease (AD), eight subjects with
dementia with Lewy bodies (DLB), five patients with frontotemporal lobar degeneration
(FTLD), five patients with mild cognitive impairment, and 29 age-matched healthy control
subjects (HC)], underwent analysis of PiB delivery and retention by means of WARM for
quantitation of [11C]PiB’s binding potentials (BPND) and correlated surrogate cerebral
blood flow (sCBF) estimates, based on the [11C]PiB images, compared to estimates by
conventional Standard Uptake Value Ratio (SUVR) of [11C]PiB retention with cerebellum
gray matter as reference. Receiver Operating Characteristics (ROC) revealed the power
of discrimination among estimates.
Results: For AD, the discriminatory power of [11C]PiB binding potential (BPND) by
WARM exceeded the power of SUVR that in turn exceeded the power of sCBF
estimates. Differences of [11C]PiB binding and sCBF measures between AD and HC
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both were highly significant (p < 0.001). For all the dementia groups as a whole, sCBF
estimates revealed the greatest discrimination between the patient and HC groups.
WARM resolves a major issue of amyloid load quantification with [11C]PiB in human
brain by determining absolute sCBF and amyloid load measures from the same images.
The two parameter approach provides key discriminary information in AD for which
[11C]PiB traditionally is used, as well as for the distinct flow deficits in FTLD, and the
marked parietal and occipital lobe flow deficits in DLB.
Conclusion: We conclude that WARM yields estimates of two important variables
that together discriminate among patients with dementia, including AD, and healthy
volunteers, with ROC that are superior to conventional methods of analysis. The
distinction between estimates of flow and amyloid load from the same dynamic emission
tomograms provides valuable pathogenetic information.
Keywords: Alzheimer’s disease, CBF, amyloid-β, [11C] PiB, flow normalization, parametric imaging
INTRODUCTION
Two properties characterize different forms of dementia, i.e.,
the degree of functional decline, and the specific pathology
leading to the functional decline. In humans, dementia is
defined by deficiency in at least two cognitive domains. The
functional decline, in turn, is linked to disturbances of brain
energy metabolism and blood flow, with changes of glucose
consumption and cerebral blood flow held to occur in parallel.
However, the pathological processes underlying the different
types of dementia in humans are poorly understood, in part
because specific evidence of the pathology and quantitative
measures of brain energy metabolism and cerebral blood are not
always available for simultaneous scrutiny, not the least when the
evidence derives from different methods that typically are not
applied at the same time.
The loss of functional integrity associated with dementia
is reflected in impairments of brain energy metabolism and
blood flow that commonly are determined by mapping of one
or more indices of brain function, including maps of brain
glucose consumption obtained by means of positron emission
tomography (PET; Rodell et al., 2013), or maps of cerebral
blood flow obtained by any one of a number of PET and
magnetic resonance imaging (MRI) techniques (Johannsen et al.,
2000; Rodell et al., 2012). Brain functional decline may result
from different pathogenetic processes in different forms of
dementia, however. Damage to dendritic spines with impairment
of the coupling of flow and metabolism to the excitation of
post-synaptic neurons may be common to processes of brain
functional decline in dementia (Penzes et al., 2011).
Alzheimer’s disease (AD) is the most common type of
dementia, aﬄicting more than 20 million victims worldwide. The
definitive diagnosis of AD requires post-mortem identification of
senile plaques of amyloid-beta (Aβ) protein and neurofibrillary
tangles of tau protein (McKhann et al., 1984; Dubois et al., 2007),
but the etiology of AD is poorly understood, and the causative
role of senile plaques is debated.
The amyloid cascade hypothesis claims that erroneous
cleavage of the amyloid precursor protein (APP) generates Aβ
that accumulates as senile plaques, associated with damage to
dendritic spines and loss of functional connectivity (Hardy and
Higgins, 1992; Hardy and Selkoe, 2002, Harrison and Owen,
2016). The resulting dementia of Alzheimer’s type is associated
with degeneration of specific functional networks, and regionally
differentiated degrees of amyloid deposition that may explain
part of the clinical heterogeneity of symptoms (Lehmann et al.,
2013) and hence may be important to diagnosis and prognosis.
Of the multiple potential paths to functional decline,
amyloid deposition is not the exclusive marker, with markers of
other pathogenetic processes suggesting paths to other types of
dementia, such as Lewy Body Dementia (DLB) or frontotemporal
lobar degeneration (FTLD). The diversity of pathologies
underlying the functional decline in dementia raises the need for
comparative evidence from functional and pathological markers
that distinguish among the different types of dementia. In these
disorders, the relationship between the pathological changes and
the changes of brain energy metabolism and blood flow is not
fully understood. An approapriate approach would assess both
markers of brain pathology and functional integrity.
The pathology associated with specific types of dementia,
notably AD, can be detected by means of a specific marker of the
presence of Aβ, by means of Pittsburgh Compound B, [11C]PiB, a
tracer used with PET (Cohen et al., 2012), or widespread clinically
with [18F]-labeled amyloid PET tracers. While [11C]PiB is useful
in the differential diagnosis between AD and FTLD, it is not alone
useful in differentiating AD from DLB, where 70–80% of the cases
present with Aβ pathology.
Recently, we exploited a particular property of the brain
uptake of [11C]PiB to show that it is possible to simultaneously
extract a functional index in terms of an absolute measure of
cerebral blood flow, as well as a pathological index in terms
of the absolute degree of binding of [11C]PiB in brain tissue,
both obtained with the Washout Allometric Reference Method
(WARM; Rodell et al., 2013). By application of WARM, we
showed that it is possible to use maps of brain uptake of [11C]PiB
to simultaneously determine a surrogate measure of absolute
cerebral blood flow and a measure of amyloid-beta accumulation
in brain. The quantitation depends on the rapid initial clearance
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of [11C]PiB from the circulation, which is consistent with the
initial flow-limited uptake of [11C]PiB, such that kinetic analyses
of the uptake and binding take both blood flow and washout into
account in a manner that couples Aβ plaque load to the cerebral
blood flow (Johannsen et al., 2000), including the loss of flow
variability observed in AD (Rodell et al., 2012).
Given the novel WARM-based identification of both [11C]PiB
binding, estimated from the rate of tracer washout as an index
of amyloid load, and an index of blood flow, estimated from
the intitial flow-dependent [11C]PiB brain distribution as a
marker of functional activity, we here test the hypothesis that
the degree of correlation between plaque load and the blood flow
index accurately differentiates among the four different forms of
dementia or degeneration examined here.
MATERIALS AND METHODS
The flow-independent WARM (Rodell et al., 2013) addresses
both the flow-dependent accumulation and the rapid clearance
of [11C]PiB from the circulation. Here, we evaluate the estimates
of the two variables generated by WARM, in order to determine
the usefulness of each as a diagnostic of dementia, and specifically
of DAT. We weighed the estimates against the conventional
Standard Uptake Value Ratio (SUVR). In order to make
the analysis independent of a specific threshold, we report
the Receiver Operating Characteristic (ROC) curves for each
method, as calculated from a data set of subjects with different
dementias and healthy age-matched volunteers.
Subjects
Twenty-nine aged individuals with well-documented normal
cognitive function (HC), 16 patients with mild to moderate AD,
8 patients with DLB, 5 patients with FTLD, and 5 subjects with
MCI, previously described by Rowe et al. (2007), were re-analyzed
for flow-independent BPND and sCBF estimates, using WARM
(Rodell et al., 2013). Normal volunteers originally recruited
from a cohort of subjects participating in the longitudinal
Healthy Aging Study at the Mental Health Research Institute
of Victoria were shown to have normal cognitive performance
on neuropsychological testing that included California Verbal
Learning Test (CVLT II), Rey figure, Logical Memory, verbal
and categorical fluency, Boston Naming Task, and digit
span. All subjects in the current study were assessed with
this neuropsychological test battery, the Mini-Mental State
Examination (MMSE), and the Clinical Dementia Rating within
1 week of the PiB PET acquisition. All AD patients met National
Institute of Neurological and Communication Disorders and
Stroke and the AD and Related Disorders Association criteria
for probable Alzheimer’s disease (pAD), whereas all subjects in
the DLB group met the consensus criteria for probable DLB of
cognitive fluctuation, visual hallucinations, and parkinsonism.
FTLD subjects had characteristic clinical presentation and
frontal lobe or temporal lobe atrophy on MRI with concordant
hypometabolism on fluorodeoxyglucose PET. The MCI subjects
met the Petersen criteria of subjective and objective cognitive
difficulties, predominantly affecting memory, in the absence of
dementia or significant functional loss (Petersen et al., 1999).
All patients were recruited from the Austin Health Memory
Disorders and Neurobehavioral Clinics, and further details can
be found in Rowe et al. (2007). The SUVR measures of [11C]PiB
retention previously were published for subjects and healthy
volunteers used in the present study (Rowe et al., 2007) while
BPND and sCBF measures were not previously obtained or
reported.
Positron Emission Tomography
Image Acquisition
All subjects had dynamic [11C]PiB PET acquisitions. [11C]PiB
was produced at Centre for PET, Austin Hospital, using the
one-step [11C]methyltriflate approach (Wilson et al., 2004) The
average radiochemical yield was 30% after 45 min synthesis
with radiochemical purity of >98% and specific activity of
30 ± 7.5 GBq/µmol. Each subject received 375 MBq [11C]PiB by
IV injection over 1 min. PET acquisitions were carried out on
a Phillips Allegro PET device. Rotation transmission sinogram
acquisition in three-dimensional mode was made with a single
[137Cs] point source before the injection of the radiotracer for
attenuation correction. A 90-min list-mode emission acquisition
was performed in three-dimensional mode after injection of
[11C]PiB. List-mode raw data were sorted off line into 4 × 30-s,
9 × 1-min, 3 × 3-min, 10 × 6-min, and 2 × 10-min frames. The
sorted sinograms were reconstructed using a three-dimensional
RAMLA algorithm.
Image Registration and Segmentation
Summed emission scans of [11C]PiB uptake were automatically
co-registered to a standardized mean [11C]PiB image in
common stereotactic space (ICBM, Montreal Neurological
Institute; Mazziotta et al., 2001) using a six-parameter affine
transformation. We did not use individual MR anatomical
images. After calculation of the final linear PET-Talairach
transformations, dynamic emission scans were re-sampled into
common coordinates. Regional BPND, R1, SUVR, and sCBF
measures (see below) were obtained from parametric PET image
maps using standard modelbased segmentation (Collins et al.,
1994; Grabner et al., 2006). The regions analyzed included left
and right frontal (FL), occipital (OL), parietal (PL), and temporal
(TL) lobes, as well as white matter (WM) and the cerebellar grey
matter (CERB).
Quantification of [11C]PiB Variables
Reference Region Ratio Measure (SUVR)
[11C]PiB retention can be calculated by determining the
accumulation relative to a reference tissue, to obtain a ratio
measure (SUVR). The ratio measure is the fraction of the region-
of-interest integral of [11C]PiB accumulation at steady-state,
assumed to have been established no later than this time after
injection (ts = 40 min), extended to the end (te = 60 min),
relative to the integral of the [11C]PiB accumulation observed in
the same period in the reference region. In the reference region,
the accumulated tracer as function of time,mND(t), represents the
non-specific bound tracer after delivery by homogeneous flow to
all voxels of the reference region. We further assumed the interval
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from ts = 40 min to te = 60 min to be sufficient to establish
steady-state (secular equilibrium) in all regions, as required by
the definition of the volume of distribution of the tracer, VT, as
the sum of the volumes of distribution of non-displaceable tracer
(VND) and the additional volume of distribution of reversibly
bound tracer.
Washout Allometric Reference Method (WARM)
In the case of negligible contribution from the circulation
after the initial brief uptake, the tissue time-activity curves of
the radio ligand are established by the radioactivity initially
dispersed to the tissue and the subsequent washout from the
brain regions of uptake. WARM (Rodell et al., 2013) specifically
takes this property into account and uses only the differences
among washout rates from regions with different properties of
binding, blood flow rates, and blood-brain barrier permeability
to determine the binding of the tracer. For direct calculation
without linearization, BPND can be found using the operational
equation (Rodell et al., 2013),
BPND(T) = m(0)
∫ T
0 ((ln(mND(t)))−(ln(mND(0))))dt
mND(0)
∫ T
0 ((ln(m(t)))−(ln(m(0))))dt
−1 (1)
where mND(t) represents the non-specifically bound tracer
following delivery by the circulation, and m(t) represents the
tracer in any other region as function of time t, where T
represents the specific time T after injection of the tracer. Due
to the rapid clearance of the tracer from the circulation, analysis
of the dynamic [11C]PiB image data revealed an initial high-
frequency signal of arterial origin in the first 2 min of acquisition,
followed first by a peak within the time frame 2–10 min, from
which time washout prevailed. For WARM, we split the signal
into the three time frames of, first, arterial phase, second, peak
uptake, and third, washout. We used the peak value within the
2–10 min interval for estimation of the relative uptake coefficient
RPiB relative to the cerebellum grey matter value. In order to
calculate the calibrated sCBF, we estimated the slope of the rise to
the peak as the ratio of the peak value to the time spent to reach
the peak (peak value/time to peak) of the [11C]PiB signal.
We used the phase of washout from the peak in the time
interval 2–60 min of dynamic image data for estimation of the
binding potential BPND (Rodell et al., 2013). BPND is is derived
in Eq. (1). When log-transformed, in the fraction part of the
equation, the nominator is the accumulated log-signal for the
reference tissue, relative to the tracer present before washout (i.e.,
the tracer that is left, compared to the tracer initially deposited
in the reference region). We scaled this difference by the initial
tracer uptake into the ROI region. The denominator similarly
describes the accumulated log-signal for a ROI or voxel relative
to how much was initially present before washout. This difference
is scaled by the start amount of the reference region. Thus the
fraction is corrected both for flow, i.e., initially deposited tracer,
and for the exponential behavior of the washout (Rodell et al.,
2013).
In order to test the power of WARM to distinguish the
dementia (AD, DLB, FTLD) and, MCI from the HC group by
quantification of the amount of retention, we extracted regional
parametric values for the [11C]PiB retention from the parametric
images with the different approaches of WARM and SUVR.
For WARM, we reported mean absolute BPND values, and for
SUVR we extracted fractional values of the area under the curves
(40–60 min), relative to the cerebelum gray matter values. As
no calibration values of sCBF from PET measures based on
[15O]water were available for this data set, we used a site-specific
scale factor to obtain a simulated absolute flow estimate from the
peak tracer arrival characteristics. The factor was derived as an
offset for the blinded data set, with a target of the corresponding
mean CBF value reported by Rodell et al. (2013). While the
use of a scaling factor may not yield absolute flow measures,
the test-specific values are stable as intrasubject comparisons
when afhered to a particular site and protocol, also without a
[15O]water calibration, in contrast to the fractional RPiB values.
We used the scaling factor in order to facilitate comparison to the
findings reported by Rodell et al. (2013).
Receiver Operating Characteristics
Receiver operating characteristic curves define a cutoff value for
clinical testing (Senanarong et al., 2012). Here, we determined the
test threshold as the coordinates of the point of the ROC curve
closest to the upper left corner of the ROC curve. We obtained
an additional important measure of the accuracy of the clinical
test as the area under the ROC curve. This discrimination is
reliable when both sensitivity and specificity are close to 1.0, with
minimal false positive and negative findings.
RESULTS
Separate Brain Images from the Two
Phases of Tracer Kinetics
Due to the rapid clearance of the tracer from the circulation, the
dynamic [11C]PiB image data revealed an initial high-frequency
signal of arterial origin in the first 2 min, consistent with a peak
within the 2–10 min interval, followed by the washout phase.
For the application of WARM, we split the signal into three
time intervals of arterial phase, peak uptake phase, and washout
phase. We used the maximum peak within the 2–10 min peak
uptake phase to estimate the relative uptake coefficient R1 and
the calibrated surrogate CBF index (sCBF) directly from the
[11C]PiB signal. We used the washout phase from the maximum
of the peak phase within the 2–60 min dynamic acquisition
to estimate the binding potential BPND of [11C]PiB. The two
derived images are then defined as the sCBF image obtained
from the initial uptake, and the BPND image obtained from the
washout part when the tracer deposit is complete and washout
occurs relative to the initial deposit. Figure 1 presents the
two time-averaged images of sCBF and BPND for each of the
groups.
High Amyloid Deposition and Decreased
Blood Flow in AD
For AD, we confirmed very significant (P < 0.0001) increases
of [11C]PiB binding by both the SUVR and BPND measures in
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FIGURE 1 | Average images for each diagnostic group (DLB, AD, FTLD, MCI) and HC, for binding potential (BPND) and sCBF measures.
the FL, PL, TL, and OL regions, and for the SUVR measure
also a significant (P < 0.01) difference in the reference region
where we had predicted no specific binding. The BPND measure
revealed increased binding in WM, assumed to represent
radioactivity spillover from the significant cortical binding in
general. Examination of individual contributions revealed less
binding estimated as BPND in the OL region than in the FL,
TL, and PL regions in every individual. Three individuals with
markedly high binding in the OL region also revealed the highest
retention in the remaining regions, suggesting that the OL region
might be the last region to be affected by amyloid deposition.
Although the binding in the AD patients was the more significant
measure, the group as a whole had marked decrease of the sCBF
estimate, particularly in FL and PL.
In the MCI category, BPND estimates were significantly higher
(P < 0.001), with three of the five patients having AD-like tracer
retention in the PL, TL, FL, and OL regions as shown in Figure 2
(MCI). As seen in Figure 3, the BPND measure was an order of
magnitude higher than for the SUVR measure. Of all cortical
lobes, the OL region was the least affected. This pattern was
similar for the sCBF measure that was not significantly different
in the OL region but was significantly lower (P < 0.05) in the TL,
Pl, and FL regions.
Low Amyloid Deposition and Decreased
Blood Flow in DLB
Only two of the eight patients diagnosed with DLB had high
[11C]PiB retention, as shown in Figure 2 (DLB), sufficient to
distinguish the group as a whole from the HC for the FL, PL, TL,
and OL regions. The BPND obtained with WARM distinguished
the group more significantly from HC than the SUVR measure, as
shown in Figure 3. In contrast, the sCBF measure revealed very
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FIGURE 2 | Single individual subject values vary in relation to the normal variation of the members of the HC group, for each region (FL, PL, TL, OL,
CB, WM) of each subject. Both sCBF and BPND variability values for different cortical regions and white matter are plotted for each diagnostic group. The figure
shows how values differ relative to the mean of healthy controls. The dotted zero-lines represent the normalized averages of the healthy control subjects. Solid blue
lines are normalized standard deviations of the group of healthy volunteers.
significantly reduced blood flow compared to healthy volunteers.
The decrease was most pronounced (P < 0.001) for the OL
region, followed by the PL region (P∼ 0.002), while the TL
(P < 0.01) and FL (P < 0.05) regions had less markedly reduced
blood flow. The decrease in this group is is in contrast to the
finindgs in the AD and MCI groups, in which the OL region
remained the least affected of the cortical lobes.
No Amyloid Deposition and Markedly
Reduced Frontal Lobe Blood Flow in
FTLD
Patients with FTLD had low [11C]PiB retention when compared
to the HC group, expressed as the binding potential BPND,
in agreement with findings previously reported as SUVR by
Rowe et al. (2007). In contrast, this small group of patients had
significantly reduced blood flow measured as sCBF in the FL
region (P < 0.007) and cerebellum (P < 0.05), presented in
Figures 2 and 3. When normalized to cerebellum, the decrease of
sCBF in FL remained significant. The SUVR, measure indicated
significant increases in the WM, but the BPND measure by
WARM did not confirm the increase.
Correlations between BPND and sCBF
Measures
While all dementia groups on average revealed lower cortical
blood flow regardless of diagnosis, only the AD and MCI groups
had unequivocal correlations with [11C]PiB retention, expressed
as the tracer BPND and sCBF measures, respectively. Figure 4
shows the mean images of the R1 and sCBF values for the AD
and HC groups, as well as the distinguishing relations of the R1
and sCBF estimates to the BPND binding measures for unilateral
values in the FL, PL, TL, and OL regions of each subject. The
BPND measure was inversely related to the sCBF measure in AD,
but the relative flow measure R1 had no correlation.
Of the eight DLB subjects, two had very high values of cortical
[11C]PiB binding, but only one had a marked decrease of the
sCBF estimate, compared to the healthy control condition. Three
DLB subjects had moderate binding of [11C]PiB together with
decreased sCBF values, while two had normal cortical BPND
values as well as slightly decreased sCBF values, as illustrated in
Figure 2 (DLB).
The images of members of the FTLD group were interpreted as
normal with respect to [11C]PiB binding, but they all had marked
frontal sCBF deficits, as illustrated in Figures 2 and 3. The deficits
were also visible on the relative (R1) flow images (not shown). The
[11C]PiB binding and sCBF indices in cerebellum and occipital
cortex appeared unaffected by FTLD.
As 60% of the MCI patients had the typical AD pattern with
high cortical [11C]PiB binding and low flow, the group result is
comparable to the AD but with less marked findings, as illustrated
in Figures 2 and 3.
Receiver Operating Characteristics
Figure 5 shows the areas under the ROC curves for all cortical
regions, as well as cerebellum gray matter and WM. Separate
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FIGURE 3 | The reciprocal of the statistical significance measure P (obtained by the Student t-test) of each diagnostic group versus HC for each
parameter. The graphs indicate the importance of each of the two parameters for identification of the disease group in comparison to the healthy control subjects.
The cerebellum gray matter was used as reference for the binding calculation, and results for this region are depicted with the open circles.
plots represent a separate diagnostic group, with the integral of
the ROC curve plotted for each of them. Areas close to unity
represent high incidences of true positives and low incidences of
false negatives, consistent with higher diagnostic accuracy. Areas
close to 0.5 indicate ROC curves close to the line of identity
at which there is no difference between the distributions of the
values of patients and healthy volunteers, i.e., a minimum of
diagnostic discrimination, as expected of a true reference region.
AUC measures are shown in Figure 5. For the AD group of
subjects, ROC areas for the cortex implied that BPND estimates
determined with WARM had the highest power of discrimination
among patients and healthy volunteers, followed by the SUVR
and sCBF but only the BPND estimates were significantly different
(P < 0.05) from sCBF estimates in pairwise ROC comparisons
of the three methods (DeLong et al., 1988). Interestingly, only
the BPND measures were significantly superior (P < 0.05)
determinants to the MMSE scores (data not shown). For the
MCI group, the ROC areas were not significantly different for the
SUVR and BPND estimates, but somewhat higher for the FL, PL,
and TL regions. However, for the FL region, the sCBF estimates as
determinants were significantly superior to the SUVR estimates
(P < 0.05).
For the DLB group of subjects, the measures that most
significantly distinguished the patients from the HC group of
subjects included declines of the sCBF values in the CORTEX
(P< 0.05 compared to BPND) and PL and TL (P< 0.05 compared
to BPND and SUVR) regions, in contrast to the MCI and AD
groups of subjects in whom flow declines in FL and [11C]PiB
retention in the PL, TL, and FL regions were more distinct than
in the OL region, although all three measures for the AD group
of subjects were not significantly different in single regions alone.
Also for the AD and MCI groups of subjects, the sCBF measure
in the OL region was less affected than in the PL, TL, and FL
regions. For FTLD, the ROC area of the sCBF measure was a
significantly superior (P < 0.05) discriminator compared to the
SUVR measure of the FL only.
DISCUSSION
The novel WARM analysis (Rodell et al., 2013) yields quantitative
measures both of the surrogate absolute blood flow value and
of the binding potential of the amyloid-β-avid tracer [11C]PiB.
The aim of this study was to evaluate the power of the
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FIGURE 4 | Upper panels show mean values of R1 and sCBF for comparison of AD to HC groups. Lower panels illustrate how relative R1 and absolute
sCBF measures differ in relation to BPND measures. Blue dots represent HC regional values (unilateral values of FL, PL, TL, and OL) and magenta dots represent
similar regional values for AD subjects.
analysis to distinguish among and between aging and different
diagnostic groups associated with neurodegenerative disorders
(Fast et al., 2013; Gjedde et al., 2013). The major findings of
the study include the delineation of the pathophysiology of
the individual diagnostic groups along the two orthogonal axes
of the measure of Aβ deposits and the measure of cerebral
blood flow. This property of WARM allowed us to distinguish
among the different forms of dementia by two-dimensional
plotting of the results. The distinctive patterns were evident
from the relationships among the magnitudes of functional
decline, identified from the measure of blood flow, and the
degree of pathology, identified from the measure of amyloid-
β load, both obtained from a single dynamic PET imaging
session.
We determined the two key measures from different temporal
intervals of the PiB uptake dynamics. The two measures
included the sCBF, the patient-specific blood flow measure that
is decisively different from the relative perfusion measure R1,
and the binding potential BPND, both revealed by WARM. All
dementia groups, regardless of diagnosis, had significantly lower
cortical flow, expressed as sCBF than the healthy volunteers,
while only the AD and MCI diagnostic groups had unequivocally
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FIGURE 5 | Areas under receiver-operating curves (ROC) for all regions, ±SEM, including cortex, frontal (FL), parietal (PL), temporal (TL), and
occipital (OL) lobes as well as cerebellum gray matter and white matter (WM). Each separate graph represents a single diagnostic group (AD, DLB, MCI,
FTLD). The integral of the ROC curve is plotted for each variable. Areas close to unity represent a high level of true positives and low level of false negatives, i.e.,
higher diagnostic certainty. Areas close to 0.5 means that the ROC curve is close to the line of unity at which there is no difference among the distributions of values
in the pathological condition and in the group of the HC, i.e., least disease discrimination, as expected for the reference region.
elevated [11C]PiB retention, expressed as the binding potential of
the tracer (BPND).
Importantly, this observation implies that the reduction of
blood flow is the functionally relevant measure, while the elevated
BPND is the result of an etiologically specific pathological process
of AD and MCI on one hand, and of DLB on the other. In the AD
and MCI groups, the BPND measure discriminated the patients
from the HC group to a greater extent than the conventional late-
timepoint SUVR measure, in part because of the flow sensitivity
of the SUVR measure, as apparent from the WM binding of
healthy controls.
Three different patterns of relative change of the two chief
measures distinguished the diagnostic group members from the
healthy control subjects, as illustrated in Figure 3. The FTLD
and DLB group members had significantly reduced flow (FTLD),
or significantly reduced flow with equally raised binding (DLB),
respectively. The AD and MCI group members had significantly
increased binding with much smaller degrees of flow reduction.
The MCI group members were characterized by the primary but
less pronounced increased binding of the tracer, compared to the
AD group members. The binding in the AD patients was the
more significant measure, but the group as a whole had marked
decrease of the sCBF estimates, particularly in FL and PL, as
previously reported by Johannsen et al. (2000). This finding is
of considerable interest because a matching decline of glucose
metabolism generally is not present (Edison et al., 2007), although
lowered metabolism generally is evident also in FL in addition
to the pathognomonic decline in parietal lobe (Gejl et al., 2012,
2013, 2014, 2016). The low flow may be a physiological reaction to
the functional decline of the diseased brain, as oxygen delivery is
commensurate with the reduced consumption of oxygen (Rodell
et al., 2012). More or less normal glucose consumption therefore
implies that a greater faction of the glucose undergoes aerobic
glycolysis only.
The [11C]PiB-derived sCBF deficits in the frontal lobe
distinguished FTLD patients from the members of the HC group
that were otherwise indistinguishable with respect to the binding
of [11C]PiB. The combination of the two measures therefore
improves the ability of [11C]PIB to discriminate between AD
(including MCI), DLB, and FTLD. A link between Aβ pathology
and functional decline in AD and MCI might be the most
likely reason for the high correlation between the flow and
binding measures in AD. The different correlations distinguished
accurately among the remaining diagnostic groups. Although
based on a small number of subjects, the finding has implications
for future combinations of other absolute flow measures using
PET or MR techniques with amyloid PET imaging, also for the
more clinically applicable [18F]-labeled tracers.
The use of WARM to derive multiparametric measures from
a single dynamic dataset more clearly differentiates among
functional and pathological features than the SUVR measure
for the individuals analysed in the present study. The study
also demonstrates that care must be taken to interpret relative
measures such as R1 with caution, as they had no determining
power, compared to the subject specific quantitative measure of
sCBF in this study (Borghammer et al., 2009a,b). The two variable
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approach is promising for other PET tracers where the rapid
disappearance from the blood stream decouples the inflow and
outflow phases of the kinetics.
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